Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ38MR)

This product GTTS-WQ38MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 608
UniProt ID Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ38MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4839MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ5107MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ8941MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ14724MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-19A
GTTS-WQ15031MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ13614MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA R1450
GTTS-WQ12924MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PankoMab
GTTS-WQ2014MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AGT-181
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW